Baird analyst Michael Ulz lowered the price target on Genocea Biosciences (NASDAQ: GNCA) to $8.00 (from $15.00) while maintaining an ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE